Acquisition Context Lodo Therapeutics was acquired by Zymergen in 2021, indicating a recent corporate consolidation and potential interest in exit opportunities or ongoing partnerships with acquirers in the biotech tooling and natural product discovery space. Business development can leverage its exit history to approach potential strategic buyers or licensing partners seeking access to environmental microbial DNA-derived compounds.

Early Stage yet Funded With a Series A of 17M and a relatively small team, Lodo sits in a lean early-stage biotech favorable for collaborators offering co-development, milestone-based partnerships, or contract research services to advance oncology-focused programs while managing risk and cost.

Strategic Partnerships Historical collaborations with global partners and ongoing interest in expanding across indications present opportunities for licensing deals, co-development arrangements, and research collaborations leveraging Lodo’s AI, sequencing, and synthetic biology platform to access novel natural product space.

Pipeline Focus Internal focus on oncology drug development combined with a platform capable of targeting undruggable targets creates sales angles for CRO services, target validation partnerships, and platform-as-a-service offerings to accelerate oncology programs for larger pharma.

IP and Asset Access Recent asset acquisitions from UCR and MSU co-founders’ work suggest available proteasome-related assets and related preclinical programs. This presents opportunities for asset licensing, collaboration on proteasome/immunoproteasome inhibitors, or research-phase asset partnerships to diversify a buyer or partner’s portfolio.